Payment overview · 2025
General Payments
$269.11
14 reported records · 8 companies
Healthcare provider profile · identity verified
Marina Behrad, MD
Allopathic & Osteopathic Physicians|Family Medicine · NOBLESVILLE, IN · NPI 1821267873
Verified facts
What the public records show
CMS Open Payments records show Marina Behrad, MD received $269.11 in general payments during 2025 across 14 reported records.
Dexcom, Inc. accounted for 29.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Shingrix.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $80.61 | 29.9% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $66.57 | 24.7% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.91 | 12.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.74 | 7.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $20.37 | 7.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.80 | 6.2% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.75 | 6.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $14.36 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $269.11 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $80.61 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $44.27 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.91 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.74 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.80 | 1 | 2025 |
Source payment records
|
|||||
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 34 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
34 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 216 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 183 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 173 | 65 |
| Lisinopril | Lisinopril | 128 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 30 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 44 |
| Omeprazole | Omeprazole | 82 | 29 |
| Simvastatin | Simvastatin | 81 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 77 | 27 |
| Gabapentin | Gabapentin | 72 | 24 |
| Losartan Potassium | Losartan Potassium | 71 | 25 |
| Alendronate Sodium | Alendronate Sodium | 66 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 27 |
| Sertraline Hcl | Sertraline Hcl | 58 | 22 |
| Buspirone Hcl | Buspirone Hcl | 57 | 20 |
| Metformin Hcl | Metformin Hcl | 57 | 22 |
| Alprazolam | Alprazolam | 56 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 56 | 17 |
| Trazodone Hcl | Trazodone Hcl | 56 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 54 | 16 |
| Eliquis | Apixaban | 51 | 14 |
| Tramadol Hcl | Tramadol Hcl | 51 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 30 |
| Potassium Chloride | Potassium Chloride | 38 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 38 | 11 |
| Azithromycin | Azithromycin | 37 | 36 |
| Metformin Hcl Er | Metformin Hcl | 36 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 34 | 12 |
| Meloxicam | Meloxicam | 34 | 13 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 34 | 29 |
| Bupropion Xl | Bupropion Hcl | 33 | 12 |
| Ozempic | Semaglutide | 33 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 14 |
| Clonazepam | Clonazepam | 30 | suppressed |
| Prednisone | Prednisone | 30 | 26 |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Furosemide | Furosemide | 29 | 12 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 28 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 27 | suppressed |
| Ezetimibe | Ezetimibe | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Chlorthalidone | Chlorthalidone | 26 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 26 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Baclofen | Baclofen | 25 | 14 |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 21 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 12 |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Progesterone | Progesterone, Micronized | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $269.11 · 14 records | Dexcom, Inc. | Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, INSPIRE, INTELLIS ADAPTIVESTIM, Korlym, PROCLAIM, SHINGRIX | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Shingrix play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error